Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

'Indian pharma companies gearing up to grab opportunities in global supply of oral Covid-19 drugs'

Indian pharma companies are gearing up to become global suppliers of repurposed Covid-19 drugs.

With the launch of new innovative Covid-19 oral drugs, Indian companies are again expected to grab opportunities in the global supply of oral Covid-19 drugs, according to data and analytics company GlobalData.


As several countries witness increasing cases of Covid-19 despite vaccination, they have started booking supply orders for innovative Covid-19 treatments like antibody cocktails, monoclonal antibodies and the latest addition such Merck's the oral Covid-19 drug ‘molnupiravir’.

Prashant Khadayate, pharma analyst at GlobalData, comments: “Oral treatment for Covid-19 would be the most convenient option for the patients ranging from mild to moderate Covid-19 and would not require a hospital setting. Currently, a majority of the Covid-19 treatments require a hospital setting.”

According to GlobalData’s Pharma Intelligence Center, the UK is the first country to approve molnupiravir which is in pre-registration stage in the US, EU and Japan.

Additionally, Pfizer submitted the emergency authorisation application of its Covid-19 drug 'paxlovid' to the US regulator on 16 November 2021.

Globally in 2022, paxlovid and molnupriavir are forecast to register sales of US$7.5bn and US$8bn respectively.

Merck has already established partnerships with five Indian companies -- Cipla, Dr Reddy’s Laboratories Limited, Emcure Pharmaceuticals, Hetero Labs and Sun Pharma -- to supply molnupiravir to India and more than 100 low- and middle-income countries.

Similarly, Pfizer has established partnership with Medicines Patent Pool (MPP) to manufacture generic versions of paxlovid to 95 low- and middle-income countries.

Khadayate concludes: “Indian generic players are popular globally to supply quality generic drugs. Moreover, Indian players have manufacturing facilities accredited by the World Health Organization and leading regulatory agencies. Based on this, Indian generic players are always preferred partners.

"In addition, Pfizer would also like to partner with the Indian players to supply paxlovid. Therefore, Indian players should be prepared to capture potential opportunities within the oral Covid-19 treatment and should be ready to supply oral COVID-19 drugs on a fast-track basis."

More For You

NHS to invest millions to boost enhanced treatment for sickle cell patients

Approximately 17,000 people live in England with sickle cell disease

Pic credit: istock

NHS to invest millions to boost enhanced treatment for sickle cell patients

The Department of Health and Social Care has announced that it will invest £9 million towards the treatment of sickle cell patients.

Approximately 17,000 people live in England with sickle cell disease. Nearly 250 new cases of this inherited blood disorder is reported annually.

Keep ReadingShow less
NHS leads the world with new ‘trojan horse’ therapy for blood cancer patients

An estimated 6,000 cases of multiple myeloma is diagnosed in the UK each year.

Pic credit: istock

NHS leads the world with new ‘trojan horse’ therapy for blood cancer patients


NHS England has become the first in the world to introduce a ‘trojan horse’ therapy for the victims of blood cancer with the ground-breaking treatment slowing down the illness three-times more than existing treatments.

Keep ReadingShow less
Call to improve inclusivity in clinical research

Ethnic minority adults continue to be underrepresented in clinical trials.

iStock

Call to improve inclusivity in clinical research

A NEW report has called for the participation of a wide range of diverse communities in clinical research to make sure that the medicines meet the needs of the UK's increasingly diverse population.

The report ‘Achieving inclusivity in clinical research’, prepared by the Association of the British Pharmaceutical Industry (ABPI) and the Association of Medical Research Charities (AMRC), highlights the long-standing challenges in ensuring diversity in clinical trials.

Keep ReadingShow less
Pharmacy students Learning Support Fund

Pharmacy students will be included in the Travel and Dual Accommodation Expenses section of the NHS Learning Support Fund.

iStock

Pharmacy students to have access to Learning Support Fund

FOR the first time in England, pharmacy students will be eligible to reimburse travel and accommodation costs while attending placements.

The Department of Health and Social Care confirmed that pharmacy students would finally be included in the Travel and Dual Accommodation Expenses (TDAE) section of the NHS Learning Support Fund (LSF).

Keep ReadingShow less
NHS for robotic surgery

Patients undergoing robotic surgery are able to recover quicker and be discharged sooner.

Pic credit: iStock

NHS pushes for robotic surgery to reduce waiting time, improve outcomes

The NHS is planning to step up robotic surgery over the next decade to reduce waiting time, help in the speed of recovery of patients, and shorter hospital stay.

As per the NHS projections, the number is expected to zoom from 70,000 in 2023/24 to half a million by 2035.

Keep ReadingShow less